PDCD1 and hepatocellular carcinoma: Following the clinical trials CheckMate-040 (9), KEYNOTE-224 (11), and IMbravel50 (114), the PD-1 inhibitors nivolumab and pembrolizumab and the PD-L1 inhibitor atezolizumab were approved for HCC treatment.